SS-31 (elamipretide): promising mitochondrial science, but not ready for your medicine cabinet

What did @kristisawicki actually say?

The creator, who holds a PhD in molecular and cellular oncology and works in genomics, walked through the basic mechanism of SS-31 (elamipretide), explaining that it enters mitochondria and binds to cardiolipin, "a fat" that holds the inner mitochondrial membrane together. When cardiolipin gets damaged, she argued, mitochondria break down, ATP drops, and cells become vulnerable to stress. She linked that dysfunction to a long list of conditions including Alzheimer's, Parkinson's, heart failure, diabetes, cancer, and chronic fatigue. She also covered primary mitochondrial myopathies, a group of inherited disorders where SS-31 was first pushed into human trials. Her overall framing was cautious for a TikTok: she consistently called the human evidence preliminary and promised to cover actual clinical trial results in a follow-up video. That restraint is worth noting because it's not common in this content category.

Does the science back this up?

On the mechanism, yes, mostly. The cardiolipin-binding story is well-documented and not contested. On the disease list, it's more complicated than she made it sound.

SS-31's interaction with cardiolipin is described in detail by Szeto (2014, Biochim Biophys Acta), who helped develop the peptide. Cardiolipin is genuinely concentrated in the inner mitochondrial membrane and plays a real structural role in the electron transport chain complexes. When cardiolipin oxidizes or gets displaced, ATP synthesis suffers. That part of her explanation holds up.

The disease list is where it gets slippery. Mitochondrial dysfunction appears in research on all the conditions she named, but that does not mean SS-31 has demonstrated meaningful effects on most of them in humans. Linking a mechanism to a long list of diseases is a well-worn rhetorical move in peptide content. It's technically defensible but functionally misleading because it implies therapeutic relevance that doesn't yet exist for most of those conditions. The strongest human data so far involves Barth syndrome and heart failure, not the broad list she rattled off.

What did they get wrong (or right)?

She got the core biochemistry right. The description of cardiolipin's role in ATP production is accurate, and her framing of mitochondrial myopathies as affecting "high energy organs" like muscle, brain, and heart is consistent with how these disorders present clinically.

She got a few things wrong or imprecise. She called the peptide "LM-peritide" when the correct name is elamipretide. She seemed aware she was guessing at the pronunciation, which is honest, but for a credentialed science communicator this is a notable slip. More substantively, she described animal findings, rats with kidney injury, aged mice with improved endurance, cardiac and neurological models, without adequately flagging that rodent mitochondrial biology does not translate cleanly to humans. Siegel et al. (2013, J Am Heart Assoc) showed promising cardiac data in dogs, but multiple human heart failure trials have had mixed results. She also restored ADP when she clearly meant ATP, a small but telling error in a video positioning itself on biochemical precision.

• Cardiolipin mechanism: accurate
• Disease association list: overstated for most conditions
• Animal-to-human translation: insufficiently caveated
• Pronunciation and name of peptide: incorrect
• ATP vs ADP slip: minor but notable

What should you actually know?

SS-31 is one of the more seriously studied peptides in this space, which is a low bar, but it's a real one. It is not a supplement you can legally obtain from a pharmacy without a prescription, and compounded versions circulating in the biohacking community are not equivalent to the pharmaceutical-grade elamipretide studied in trials.

The most concrete human evidence comes from Barth syndrome, a rare genetic disorder affecting cardiolipin metabolism. A randomized trial by Bhatt et al. (2023, NEJM Evidence) showed statistically significant improvements in exercise capacity in Barth syndrome patients. That is meaningful. For heart failure, results have been more mixed, and for conditions like Alzheimer's or chronic fatigue that she name-dropped, there is no human clinical evidence worth citing yet.

If you're seeing SS-31 promoted for general energy, aging, or performance, you are well ahead of what the evidence supports. The mechanism is interesting. The animal data is interesting. The human data is limited and disease-specific. Those are three very different things, and this video, to its credit, does not entirely collapse that distinction, though it drifts in that direction when listing diseases.